Oculis (NASDAQ:OCS) Reaches New 52-Week Low – Should You Sell?

Shares of Oculis Holding AG (NASDAQ:OCS) reached a new 52-week low on Friday . The stock traded as low as $11.29 and last traded at $11.3170, with a volume of 284111 shares. The stock had previously closed at $11.83.

Analysts Set New Price Targets

Several research analysts have recently weighed in on OCS shares. Needham & Company LLC cut their price target on Oculis from $46.00 to $38.00 and set a “buy” rating for the company in a research note on Monday. JPMorgan Chase & Co. dropped their target price on Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research report on Wednesday. Guggenheim dropped their target price on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a research report on Monday. Wall Street Zen downgraded Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Finally, Robert W. Baird cut their target price on Oculis from $49.00 to $38.00 and set an “outperform” rating for the company in a research note on Monday. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Oculis currently has a consensus rating of “Moderate Buy” and an average target price of $38.33.

Oculis Trading Down 5.4%

The firm has a 50 day simple moving average of $26.72 and a 200 day simple moving average of $25.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18. The firm has a market cap of $649.09 million, a P/E ratio of -5.26 and a beta of 0.23.

Oculis (NASDAQ:OCS) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The business had revenue of $0.26 million for the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. On average, equities research analysts predict that Oculis Holding AG will post -2.23 EPS for the current fiscal year.

Institutional Trading of Oculis

A number of large investors have recently modified their holdings of OCS. Geode Capital Management LLC boosted its position in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Oculis during the 2nd quarter valued at about $393,000. Bank of America Corp DE raised its holdings in shares of Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares in the last quarter. Woodline Partners LP raised its holdings in shares of Oculis by 65.8% during the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares in the last quarter. Finally, Aventura Private Wealth LLC purchased a new position in shares of Oculis during the 4th quarter valued at about $80,000. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.